CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Ascendis Pharma A/S

ASND
$14.17BLarge Cap

Next catalyst

Phase 2August 2027

TransCon IL-2 β/γ

Advanced Solid Tumor

Get an email about ASND's next catalysts

Track Ascendis Pharma A/S (ASND) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.

Plus 1 more upcoming event in our data (Phase 2 readout).See the timeline

Catalyst Timeline

2 upcoming, 1 past

Phase 2Next

TransCon IL-2 β/γ Phase 2 Est. Readout (IL Believe)

August 2027~TransCon IL-2 β/γ320

Primary completion for TransCon IL-2 β/γ trial (NCT05081609) in Advanced Solid Tumor

Source
Phase 2

Navepegritide Phase 2 Est. Readout (teACH)

September 2027~Navepegritide25

Primary completion for Navepegritide trial (NCT06732895) in Achondroplasia

Source

How ASND's past catalysts played out

Market Overview

Stock performance and key metrics

NASDAQPharmaceutical Preparations🇺🇸EuropeHELLERUP1.0K employees
Website
Drug Pipeline

Frequently asked questions

What is in Ascendis Pharma A/S's drug pipeline?→

CatalystAlert tracks 13 drug candidates in Ascendis Pharma A/S's (ASND) pipeline across Phase 3, Phase 2. Its lead program is Lonapegsomatropin (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is Ascendis Pharma A/S's next FDA catalyst?→

Ascendis Pharma A/S's (ASND) next tracked catalyst is a Phase 2 readout expected August 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.

How do I track ASND biotech catalysts?→

Add ASND to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Ascendis Pharma A/S's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply